High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma

World Journal of Surgery

Volumn 31, Issue 3, 2007, Pages 503-

  Schindl, M J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE; UROKINASE RECEPTOR;

CANCER SURVIVAL; CORRELATION ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; NOTE; PANCREAS ADENOCARCINOMA; PREDICTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA ANALYSIS;

EID: 33847642256     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-006-0869-8     Document Type: Note

References (4)

1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363(9414): 1049-57.
2. Garcea G, Neal CP, Pattenden CJ, et al. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005;41(15): 2213-36.
3. Abi-Habib RJ, Singh R, Liu S, et al. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Mol Cancer Ther 2006;5(10):2556-62.
4. Grutzmann R, Boriss H, Ammerpohl O, et al. Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 2005;24(32):5079-88.